Toxicological research has identified several biomarkers that may aid in the early detection and diagnosis of bladder cancer. These include genetic mutations, protein expressions, and metabolites in urine. Biomarkers can potentially improve screening and monitoring, allowing for earlier intervention and better outcomes.
